Disturbed in vitro adrenergic modulation of cytokine production in inflammatory bowel diseases in remission

Journal of Neuroimmunology

Volumn 182, Issue 1-2, 2007, Pages 195-203

  Lucas, A ^a   Cobelens, P M ^a,b   Kavelaars, A ^b   Heijnen, C J ^b   Holtmann, G ^d   Haag, S ^a   Gerken, G ^a   Langhorst, J ^e   Dobos, G J ^e   Schedlowski, M ^c   Elsenbruch, S ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ETH ZURICH   (Switzerland)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Cytokines; Glucocorticoid sensitivity; Inflammatory bowel diseases; Irritable bowel syndrome; Psychoneuroimmunology

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOKINE; DEXAMETHASONE; GLUCOCORTICOID; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; TERBUTALINE; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC ACTIVITY; ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMOGRAPHY; DIARRHEA; ENTERITIS; FEMALE; GASTROENTERITIS; HUMAN; IRRITABLE COLON; MALE; MENTAL STRESS; MONOCYTE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; QUALITY OF LIFE; REMISSION;

ADRENERGIC BETA-AGONISTS; ADULT; DEXAMETHASONE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROENTERITIS; GLUCOCORTICOIDS; HUMANS; INFECTION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MIDDLE AGED; MONOCYTES; REMISSION INDUCTION; TERBUTALINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845890268     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.09.011     Document Type: Article

References (52)

1. Bercik, P., Verdu, E.F., Collins, S.M., 2005. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol. Clin. North Am. 34:235-vii.
2. Best W.R., Becktel J.M., Singleton J.W., and Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976) 439-444
3. Bitton A., Sewitch M.J., Peppercorn M.A., et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am. J. Gastroenterol. 98 (2003) 2203-2208
4. Bradesi S., McRoberts J.A., Anton P.A., and Mayer E.A. Inflammatory bowel disease and irritable bowel syndrome: separate or unified?. Curr. Opin. Gastroenterol. 19 (2003) 336-342
5. Chadwick V.S., Chen W., Shu D., et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122 (2002) 1778-1783
6. Collins S.M. Dysregulation of peripheral cytokine production in irritable bowel syndrome. Am. J. Gastroenterol. 100 (2005) 2517-2518
7. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., and de Vries J.E. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174 (1991) 1209-1220
8. Dinan T.G., Quigley E.M., Ahmed S.M., et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?. Gastroenterology 130 (2006) 304-311
9. Drossman D.A., Corazziari E., Talley N.J., Thompson W.G., and Whitehead W.E. In: McLean V.A. (Ed). Rome II. The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology And Treatment: A Multinational Consensus. 2nd ed. (2000), Degnon Associates Inc, McLean
10. Dunlop S.P., Jenkins D., Neal K.R., and Spiller R.C. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 125 (2003) 1651-1659
11. Ebert E.C., Mehta V., and Das K.M. Activation antigens on colonic T cells in inflammatory bowel disease: effects of IL-10. Clin. Exp. Immunol. 140 (2005) 157-165
12. Eijkelkamp N., Cobelens P.M., Sanders V.M., Heijnen C.J., and Kavelaars A. Tissue specific effects of the beta 2-adrenergic agonist salbutamol on LPS-induced IFN-gamma, IL-10 and TGF-beta responses in vivo. J. Neuroimmunol. 150 (2004) 3-9
13. Elsenbruch S., and Orr W.C. Diarrhea- and constipation-predominant IBS patients differ in postprandial autonomic and cortisol responses. Am. J. Gastroenterol. 96 (2001) 460-466
14. Farhadi A., Keshavarzian A., Van de Kar L.D., et al. Heightened responses to stressors in patients with inflammatory bowel disease. Am. J. Gastroenterol. 100 (2005) 1796-1804
15. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115 (1998) 182-205
16. Garrett V.D., Brantley P.J., Jones G.N., and McKnight G.T. The relation between daily stress and Crohn's disease. J. Behav. Med. 14 (1991) 87-96
17. Gonsalkorale W.M., Perrey C., Pravica V., Whorwell P.J., and Hutchinson I.V. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?. Gut 52 (2003) 91-93
18. Greene B.R., Blanchard E.B., and Wan C.K. Long-term monitoring of psychosocial stress and symptomatology in inflammatory bowel disease. Behav. Res. Ther. 32 (1994) 217-226
19. Gwee K.A., Collins S.M., Read N.W., et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 52 (2003) 523-526
20. Gwee K.A., Leong Y.L., Graham C., et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 44 (1999) 400-406
21. Häuser W., Dietz N., Grandt D., et al. Validation of the inflammatory bowel disease questionnaire IBDQ-D, German version, for patients with ileal pouch anal anastomosis for ulcerative colitis. Z. Gastroenterol. 42 (2004) 131-139
22. Heesen C., Gold S.M., Sondermann J., Tessmer W., and Schulz K.H. Oral terbutaline differentially affects cytokine (IL-10, IL-12, TNF, IFNg) release in multiple sclerosis patients and controls. J. Neuroimmunol. 132 (2002) 189-195
23. Holtmann G., Goebell H., Holtmann M., and Talley N.J. Dyspepsia in healthy blood donors. Pattern of symptoms and association with Helicobacter pylori. Dig. Dis. Sci. 39 (1994) 1090-1098
24. Jacobs R., Pawlak C.R., Mikeska E., et al. Systemic lupus erythematosus and rheumatoid arthritis patients differ from healthy controls in their cytokine pattern after stress exposure. Rheumatology (Oxford) 40 (2001) 868-875
25. Kavelaars A., van de Pol M., Zijlstra J., and Heijnen C.J. Beta 2-adrenergic activation enhances interleukin-8 production by human monocytes. J. Neuroimmunol. 77 (1997) 211-216
26. Kühn R., Löhler J., Rennick D., Rajewsky K., and Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993) 263-274
27. Levenstein S., Prantera C., Varvo V., et al. Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study. Am. J. Gastroenterol. 89 (1994) 1219-1225
28. Levenstein S., Prantera C., Varvo V., et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am. J. Gastroenterol. 95 (2000) 1213-1220
29. Lombardi M.S., Kavelaars A., Schedlowski M., et al. Decreased expression and activity of G-protein-coupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis. FASEB J. 13 (1999) 715-725
30. Maunder R.G. Evidence that stress contributes to inflammatory bowel disease: evaluation, synthesis, and future directions. Inflamm. Bowel Dis. 11 (2005) 600-608
31. Mawdsley J.E., and Rampton D.S. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 54 (2005) 1481-1491
32. Mayer E.A., and Collins S.M. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 122 (2002) 2032-2048
33. Mayer E.A., Naliboff B.D., Chang L., and Coutinho S.V. Stress and irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 280 (2001) G519-G524
34. Mittermaier C., Dejaco C., Waldhoer T., et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom. Med. 66 (2004) 79-84
35. Monnikes H., Tebbe J.J., Hildebrandt M., et al. Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity. Dig. Dis. 19 (2001) 201-211
36. O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128 (2005) 541-551
37. Padgett D.A., and Glaser R. How stress influences the immune response. Trends Immunol. 24 (2003) 444-448
38. Podolsky D.K. Lessons from genetic models of inflammatory bowel disease. Acta Gastro-Enterol. Belg. 60 (1997) 163-165
39. Quigley E.M. Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?. Chin. J. Dig. Dis. 6 (2005) 122-132
40. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298 (1989) 82-86
41. Rogler G., and Andus T. Cytokines in inflammatory bowel disease. World J. Surg. 22 (1998) 382-389
42. Rogler G., Meinel A., Lingauer A., et al. Glucocorticoid receptors are down-regulated in inflamed colonic mucosa but not in peripheral blood mononuclear cells from patients with inflammatory bowel disease. Eur. J. Clin. Investig. 29 (1999) 330-336
43. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122 (2002) 512-530
44. Schreiber S., Heinig T., Thiele H.G., and Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108 (1995) 1434-1444
45. Shibolet O., Alper R., Ilan Y., and Weidenfeld J. Regulatory role of the pituitary-adrenal axis in experimental colitis: effect of adrenalectomy on the clinical course and the TH1/TH2 immune profile. Inflamm. Bowel Dis. 11 (2005) 1053-1059
46. Spiller R.C. Infection, immune function, and functional gut disorders. Clin. Gastroenterol. Hepatol. 2 (2004) 445-455
47. Straub R.H., Herfarth H., Falk W., Andus T., and Schölmerich J. Uncoupling of the sympathetic nervous0020system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease?. J. Neuroimmunol. 126 (2002) 116-125
48. Tagore A., Gonsalkorale W.M., Pravica V., et al. Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 54 (1999) 386-390
49. Talley N.J., Phillips S.F., Melton J., Wiltgen C., and Zinsmeister A.R. A patient questionnaire to identify bowel disease. Ann. Intern. Med. 111 (1989) 671-674
50. van der Poll T., Coyle S.M., Barbosa K., Braxton C.C., and Lowry S.F. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J. Clin. Invest. 97 (1996) 713-719
51. van der Veek P.P., van den Berg M., de Kroon Y.E., Verspaget H.W., and Masclee A.A. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am. J. Gastroenterol. 100 (2005) 2510-2516
52. van Deventer S.J., Elson C.O., and Fedorak R.N. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 113 (1997) 383-389